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Abstract
DNA hypomethylation was previously implicated in cancer progression and metastasis. The purpose of this study was 
to examine whether stilbenoids, resveratrol and pterostilbene thought to exert anticancer effects, target genes with 
oncogenic function for de novo methylation and silencing, leading to inactivation of related signaling pathways. Following 
Illumina 450K, genome-wide DNA methylation analysis reveals that stilbenoids alter DNA methylation patterns in breast 
cancer cells. On average, 75% of differentially methylated genes have increased methylation, and these genes are enriched 
for oncogenic functions, including NOTCH signaling pathway. MAML2, a coactivator of NOTCH targets, is methylated at 
the enhancer region and transcriptionally silenced in response to stilbenoids, possibly explaining the downregulation 
of NOTCH target genes. The increased DNA methylation at MAML2 enhancer coincides with increased occupancy of 
repressive histone marks and decrease in activating marks. This condensed chromatin structure is associated with binding 
of DNMT3B and decreased occupancy of OCT1 transcription factor at MAML2 enhancer, suggesting a role of DNMT3B in 
increasing methylation of MAML2 after stilbenoid treatment. Our results deliver a novel insight into epigenetic regulation of 
oncogenic signals in cancer and provide support for epigenetic-targeting strategies as an effective anticancer approach.
Introduction
Breast cancer is the most common type of cancer in women and 
the second most commonly occurring cancer overall worldwide 
(1,2). Identification of new effective preventive and anticancer 
strategies is therefore critical. Only 5–10% of breast cancers 
are hereditary (3,4). The overwhelming majority of cases are 
sporadic, likely caused by external exposures including estro-
gens, alcohol use, physical inactivity, and poor diet (3,4). It is 
estimated that at least 30% of sporadic breast cancer cases are 
not linked to mutations but have been shown to contain epige-
netic alterations, particularly in DNA methylation (5,6).
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Epigenetics refers to alterations in gene expression without 
changes in the underlying DNA sequence and consists of three 
main components: DNA methylation, histone modifications, 
and noncoding RNA mechanisms. DNA methylation that occurs 
predominantly in CpG sequences is considered to be the gate-
keeper of gene expression providing stable long-term regulation 
(7). Simultaneously, DNA methylation has attracted a significant 
amount of attention for the prevention and treatment of dif-
ferent illnesses with cancer at the forefront, mainly due to the 
inherent reversibility of epigenetic states (8,9). Hypermethylation 
of tumor suppressor genes linked to transcriptional silencing and 
recently reported promoter hypomethylation linked to activation 
of oncogenes and prometastatic genes have been shown to play 
a role in cancer initiation, progression and metastasis (8–13).
It was generally assumed that DNA hypomethylation in 
cancer occurs mainly in repetitive, CpG-sparse regions of the 
genome (14), in contrast to DNA hypermethylation that targets 
CpG-rich islands in promoters and first exons (15). However, 
recent numerous epigenome-wide association studies indicate 
that hypomethylation also targets promoter regions or enhanc-
ers of genes that are involved in functions essential for cancer 
progression and metastasis (10,13,14). Breast cancer has been 
associated not only with hypermethylation of tumor suppres-
sor genes (5,6) but also with hypomethylation of oncogenes and 
pro-metastatic genes. For instance, re-methylation of hypo-
methylated promoter of urokinase-type plasminogen activator 
(uPA), a gene inducing metastatic cell behavior, was shown to 
block breast cancer growth and metastasis (16). Many of the 
hypomethylated genes in cancer have been shown to fall into 
oncogenic pathway categories (10). This would suggest that loci-
specific DNA hypomethylation in cancer might be associated 
with activation of oncogenic signals. Interestingly, a number of 
signaling pathways have been implicated in the development 
and progression of breast cancer and noteworthy among those 
is NOTCH signaling (17,18). The NOTCH pathway regulates cell 
proliferation, survival, differentiation, cell–cell communication, 
angiogenesis and many other processes essential for tumori-
genic potential (19,20).
It is becoming clear that there is a need for novel agents that 
will also target hypomethylated genes with oncogenic and pro-
metastatic function and lead to their methylation and silencing. 
It would be expected that such compounds remodel the DNA 
methylation states rather than cause robust on–off changes. 
They could possibly act through indirect mechanisms resulting 
in differential changes in the DNA methylation states. Naturally 
derived compounds that switch cancerous to normal phenotype 
at minimally toxic doses would be excellent candidates for sub-
tle changes in the DNA methylation profiles. Although limited, 
there are pieces of evidence demonstrating that bioactive com-
pounds found in food and herbs can modulate gene expression 
by targeting DNA methylation. Specifically, resveratrol (RSV), a 
polyphenol from stilbenoid class, reversed hypermethylation 
and silencing of BRCA1, PTEN, APC and RARbeta2 tumor suppres-
sor genes and inhibited breast cancer growth (5,6,21). Strikingly, 
RSV-mediated increase in methylation of specific genes has 
been demonstrated in recent studies in a rat diabetic model 
where methylation within pro-inflammatory cytokines led to 
their suppression in response to RSV (22). Similarly, pterostil-
bene (PTS), which is an analog of RSV, reversed hypomethyla-
tion within fasn (fatty acid synthase) gene in obesogenic rats and 
prevented subsequent gene upregulation (23). Although mecha-
nisms underlying changes in the epigenome mediated by stil-
benoids remain to be elucidated, the mode of action targeting 
both hypermethylated and hypomethylated genes in cancer is 
promising in cancer therapy and prevention.
To investigate the role of stilbenoids, RSV and PTS, in remod-
eling the DNA methylation patterns associated with cancer and 
elaborate on how these epigenetic effects correlate with the 
anticancer action of the compounds, we used isogenic breast 
cancer cell lines, lowly invasive MCF10CA1h and highly inva-
sive MCF10CA1a, as a model system. Specifically, we delineated 
genome-wide DNA methylation landscape in response to RSV 
and focused on genes that were hypomethylated in breast cancer 
and whose DNA methylation increased in response to stilbenoids. 
Among genes with the highest increases in DNA methyla-
tion upon RSV exposure, we identified MAML2 (Mastermind 
(Drosophila)-Like) that is a coactivator of the oncogenic NOTCH 
signaling pathway (19). At each step, our results are consistent 
with the hypothesis that stilbenoids target specific genes that 
are hypomethylated in cancer and encode functional pathways 
required for cell growth and invasion and that partial reversal of 
this hypomethylation process by stilbenoids coincides with inhi-
bition of cell growth and invasive properties of breast cancer cells.
Materials and methods
Cell culture and treatment with RSV and PTS
Human breast epithelial MCF10A cell line was purchased from 
American Type Culture Collection (CRL-10317, USA). Human breast can-
cer MCF10CA1h and MCF10CA1a cell lines were a gift from Dr Dorothy 
Teegarden (Purdue University). Please see Supplementary Materials, avail-
able at Carcinogenesis Online, for details on cell culture media, culture 
conditions, cell lines authentication. RSV (Sigma–Aldrich, St Louis, MO) 
and PTS (Cayman Chem., Ann Arbor, MI) were resuspended in ethanol and 
10 mM solutions were stored at −20°C. Dilutions of the compounds were 
freshly prepared prior to adding to the cell medium. Cells were grown 
in a humidified atmosphere of 5% carbon dioxide at 37°C. Twenty-four 
hours prior to treatment with RSV or PTS, cells were plated at a density 
of 2–3 × 105 per a 10-cm tissue culture dish. Cells were exposed to different 
RSV or PTS concentrations ranging from 0 to 20 µM for 4 days. Cells were 
then split 1:50, allowed to attach overnight and exposed to the compounds 
for additional 4 days (9-day exposure).
Illumina Infinium Human Methylation 450K 
BeadChip microarray
DNA from control cells (untreated) and treated cells was isolated using 
standard phenol:chloroform extraction protocol. Genomic DNA was 
processed for genome-wide DNA methylation analysis using Infinium 
HumanMethylation 450K BeadChip as described previously (24). Please see 
Supplementary Materials, available at Carcinogenesis Online, for details. The 
methylation score for each CpG was represented as a beta value according 
to the fluorescent intensity ratio with any values between 0 (unmethyl-
ated) and 1 (completely methylated). Raw microarray data and processed 
data are available from Gene Expression Omnibus (GSE80794).
Cell transfection with siRNA
Cells were plated at a density of 4–6 × 105 per 10-cm tissue culture 
dish, 24 h prior to small interfering RNA (siRNA) treatment. All siRNA 
sequences were obtained from Dharmacon, including control siRNA (siC-
trl), human MAML2 siRNA (siMAML2) and human OCT1 siRNA (siOCT1). 
The cells were transfected with siRNA using lipofectamine RNAiMAX 
(Invitrogen, Carlsbad, CA) as described previously (10). Concentration of 
Abbreviations 
RSV resveratrol 
PTS pterostilbene 
siRNA small interfering RNA 
ChIP chromatin immunoprecipitation 
qChIP quantitative chromatin immunoprecipitation
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56 nM was used for all siRNAs, which was determined as optimal in our 
previous studies (10). Please see Supplementary Materials, available at 
Carcinogenesis Online, for details on siRNA sequences and procedure. The 
transfection sequence was repeated two or three times depending on the 
effects on cell viability.
Viability, invasion and anchorage-independent 
growth assays
Cell viability was determined by trypan blue (Sigma–Aldrich) exclusion 
test. Cells were harvested after treatment with RSV or PTS on day 4 and 
day 9. Following 3–5 min incubation with trypan blue, the viable and dead 
cells were counted under the microscope. The results were confirmed by 
MTT assay (Supplementary Figure S1, available at Carcinogenesis Online). 
Similarly, the cell viability after treatment with siRNAs was evaluated by 
trypan blue exclusion test.
Anchorage-independent growth in a 3-D format that resembles an in 
vivo cellular environment (25) was determined by soft agar assay, whereas 
the ability of treated cells to invade through extracellular matrix was eval-
uated by the Cell Invasion Assay Kit (Chemicon Int.) as described previ-
ously (10). Please see Supplementary Materials, available at Carcinogenesis 
Online, for details.
DNA extraction and pyrosequencing
DNA bisulfite conversion was performed as previously described (10,26). 
Specific bisulfite-converted DNA sequences were amplified with HotStar 
Taq DNA polymerase (Qiagen) using biotinylated primers listed in 
Supplementary Table S1A, available at Carcinogenesis Online. The bioti-
nylated DNA strands were pyrosequenced in the PyroMarkTMQ24 instru-
ment (Biotage, Qiagen) as previously described (27). Data were analyzed 
using PyroMarkTMQ24 software.
RNA extraction and QPCR
Total RNA was isolated using TRIzol (Roche Diagnostics) according to 
the manufacturer’s protocol and as described previously (10). Please see 
Supplementary Materials, available at Carcinogenesis Online, for details. 
Primers used in QPCR are listed in Supplementary Table S1B, available 
at Carcinogenesis Online. Quantification was performed using a standard 
curve and analyzed by the Roche LightCycler 480 software.
Western blot analyses
Total protein extract was obtained as described previously (10). Please see 
Supplementary Materials, available at Carcinogenesis Online, for details. 
The proteins were immunoblotted with anti-MAML2 (Abcam, ab57824) or 
anti-OCT1 (Millipore, MAB5434) antibody at 1:1000 dilution, followed by a 
secondary anti-mouse (Millipore, 12–349) IgG antibody at 1:2000 dilution. 
The membranes were blotted with an anti-β-actin antibody as loading 
control (Millipore, MABT523).
ChIP and qChIP
Chromatin immunoprecipitation (ChIP) was performed as previously 
described (28,29). Please see Supplementary Materials, available at 
Carcinogenesis Online, for details. The following primary antibodies were 
used: anti-acetyl-Histone H3Lys27 rabbit antibody (H3K27ac, Millipore, 
07-360), anti-acetyl-Histone H3Lys9 rabbit antibody (H3K9ac, Millipore, 
07-352), anti-trimethyl-Histone H3Lys27 rabbit antibody (H3K27me3, 
Millipore, 07-449), anti-DNMT3B rat antibody (Millipore, MABE305) or anti-
OCT1 mouse antibody (Millipore, MAB5434). ChIP DNA was used as a tem-
plate for QPCR (quantitative ChIP [qChIP]). Twenty-five nanogram input, 
antibody-bound and IgG-bound DNA was used as starting material in all 
conditions. Levels of H3K27ac, H3K9ac, H3K27me3, DNMT3B, and OCT1 
binding were expressed as (Bound-IgG)/Input. Primers used for ChIP vali-
dation are depicted in Supplementary Table S1C, available at Carcinogenesis 
Online.
Statistical analysis
Raw methylation data from Human Methylation 450K microarrays were 
pre-processed using GenomeStudio and IMA (Illumina Methylation 
Analyzer for 450K, R/Bioconductor) including quality control, background 
correction, normalization, probe scaling and adjustment for batch effect. 
Differential methylation analysis between sample groups was conducted 
using linear models (R Bioconductor package limma). Specifically, limma 
uses an empirical Bayes moderated t-test, computed for each probe, which 
is similar to a t-test, except that standard errors have been moderated 
using information from the full set of probes (30). A methylation differ-
ence greater than 0.05 with a moderated t-test P ˂ 0.05 was considered 
statistically significant.
Statistical analysis of pyrosequencing, QPCR, qChIP, invasion, viability, 
soft agar assays was performed using the unpaired t-test with two-tailed 
distribution. Each value represents the mean ± SD of three independent 
experiments. The results were considered statistically significant when 
P < 0.05.
Results
Cancer-specific effects of RSV and PTS in inhibition 
of cell growth and invasiveness
Our hypothesis was that both RSV and PTS inhibit cancer cell 
growth and invasiveness, at least partially, through epige-
netic regulation of gene expression. High cytotoxic doses of an 
agent with potential epigenetic activity can impede epigenetic 
reprogramming (31). Hence, minimally cytotoxic doses are rec-
ommended for studying epigenetic effects as was shown for 
epigenetic drugs, 5-aza-cytidine (5-aza-CR) and 5-aza-deoxy-
cytidine (5-aza-CdR) (31). We therefore examined the effect of 
the compounds on cell growth at different concentrations using 
trypan blue exclusion test to quantify viable/death cell ratio. The 
results of cell viability were further validated by MTT assay. The 
treatments of MCF10A human immortalized mammary epithe-
lial cells (used here as a normal cell model) and MCF10CA1h and 
MCF10CA1a human breast cancer cells were conducted for 4 or 
9 days in order to establish time-dependent effects. MCF10CA1h 
and MCF10CA1a cells are derived from xenografts of MCF10A-
ras cells that were generated by transfecting MCF10A mammary 
epithelial cells with constitutively active T24 Harvey-ras onco-
gene. MCF10CA1h and MCF10CA1a cells form well-differentiated 
and poorly differentiated malignant tumors in the xenograft 
models, respectively. Thus, MCF10CA1h cells have low invasive 
properties, contrary to MCF10CA1a cells that have characteris-
tics of highly invasive phenotype. The three cell lines used in the 
present study (mammary epithelial cells, cancer lowly invasive 
and cancer highly invasive) are isogenic and thereby constitute 
an excellent model to study differential epigenetic effects dur-
ing breast cancer progression.
Treatment of both cancer cell lines with RSV or PTS resulted 
in a significant inhibition of cell growth as compared with 
control cells (treated with vehicle-ethanol) (Figure  1A and B, 
Supplementary Figure S1, available at Carcinogenesis Online). 
These effects were dose- and time dependent in both cell lines 
treated with RSV or PTS. The compounds caused 50% inhibition 
of cell viability (IC50) at doses equal to 15 µM for RSV and 7 µM for 
PTS (Figure 1A and B). Highly invasive cells were slightly more 
resistant to the treatments than lowly invasive cells. To compare 
the effects of RSV or PTS treatments in cancer cells with that 
in mammary epithelial cells, we challenged MCF10A cells with 
different doses of the compounds for 4 and 9 days. A concentra-
tion range 0–20 µM exerted only modest effects on viability of 
mammary epithelial cells (Figure 1A and B). Because the estab-
lished 50% inhibition of cell viability concentrations were mini-
mally toxic in both cancer cell lines (<10% of dead cells) and did 
not significantly affect mammary epithelial cells (>90% of cells 
viable), hence these doses were chosen for further experiments.
Stilbenoids at 50% inhibition of cell viability concentrations 
significantly reduced invasive properties of breast cancer cells 
(Figure 1C) and their ability to anchorage-independent growth, a 
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measure of oncogenesis (Figure 1D). The invasion and soft agar 
assays confirm high invasive potential of MCF10CA1a cells. The 
number of invaded cells and colonies formed in soft agar was 
nearly 2.5-fold higher for MCF10CA1a than for MCF10CA1h cells 
(Figure  1C and D). No such effects were seen in MCF10A cells 
that do not invade through the extracellular matrix and do not 
form colonies in soft agar (Figure 1C and D).
The landscape of DNA methylation in MCF10CA1h 
and MCF10CA1a breast cancer cells upon RSV 
exposure
Our previous work shows that RSV activates several methyla-
tion-silenced tumor suppressor genes in breast cancer (5,6). 
Previous data generated in epigenome-wide association studies 
Figure 1. Cancer-specific effects of RSV and PTS: inhibition of cell growth and invasive capacities. (A,B) Effect on cell growth after 4-day- and 9-day treatment with RSV 
(A) and PTS (B) at 5–20 µM concentrations in MCF10CA1h (1) and MCF10CA1a (2) breast cancer cells and in MCF10A (3) immortalized mammary epithelial cells; (C,D) 
effect on cell invasion (C) and anchorage-independent growth (D) as measured by Boyden chamber invasion assay and soft agar, respectively, upon 9-day exposure to 
15 µM RSV and 7 µM PTS. All results represent mean ± SD of three independent experiments; ***P < 0.001, **P < 0.01, *P < 0.05.
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provide increasing evidence that changes in DNA methyla-
tion are involved in cancer initiation and development (10,32). 
We reasoned therefore that reversing aberrant DNA methyla-
tion changes in cancer cells could be one of the mechanisms 
of the anticancer action of stilbenoids. Although it was demon-
strated that stilbenoids like RSV can modulate gene expression 
of candidate tumor suppressors by modifying DNA methyla-
tion (5,6,21), their effects, particularly with respect to genes 
with oncogenic functions, have yet to be addressed. This is of 
high interest as genes with oncogenic and pro-metastatic func-
tions were demonstrated to be commonly hypomethylated and 
activated in tumors versus normal tissue and drive cell trans-
formation (10,13,32–34). In order to elaborate on the effects of 
stilbenoids on DNA methylation patterns and elucidate a pos-
sible molecular mechanism, we examined, using Illumina 450K 
array, genome-wide patterns of DNA methylation in MCF10CA1h 
and MCF10CA1a cells exposed to 15 µM RSV for 9 days (Figure 2). 
Please see Supplementary Materials, available at Carcinogenesis 
Online, for details on the Illumina 450K microarray platform.
We identified 4183 differentially methylated CpG sites in 
MCF10CA1h and 6347 differentially methylated CpG sites in 
MCF10CA1a cells upon 9-day treatment with 15 µM RSV as com-
pared with control cells (differential methylation ≤−0.05 or ≥0.05, 
nominal P < 0.05, limma t-test) (Figure 2A and B). Chromosomal 
views of these differences were plotted using the Integrative 
Genomics Viewer (IGV) visualization tool (Figure 2C and D). Each 
vertical bar corresponds to a single differentially methylated 
CpG site, with blue indicating hypomethylation and red indicat-
ing hypermethylation in RSV versus control.
Most genes with tumor suppressor role in cancer have 
hypermethylated promoters and hypomethylated bodies com-
pared with normal cells, which reflects their transcriptional 
silencing. Activated oncogenes would demonstrate the oppo-
site patterns of DNA methylation. Taking into account the 
anticancer effects of RSV, we would expect that RSV treatment 
will decrease DNA methylation within promoters of potential 
tumor suppressor genes but increase DNA methylation within 
regulatory regions of potential oncogenes. Certain regions in 
the body of genes, such as CpG islands and enhancers, can play 
a regulatory role in gene transcription, thereby reflecting DNA 
methylation patterns in gene promoters. Approximately 36% 
of CpG sites whose methylation is changed upon treatment 
with RSV are located outside of gene promoters in gene bod-
ies. Interestingly, 74% of those sites in gene bodies are found 
in regulatory regions, including CpG islands and enhancers. 
Examples of such sites in MCF10CA1h and MCF10CA1a breast 
cancer cells are depicted in Supplementary Figure S2 (right 
panel, available at Carcinogenesis Online), along with maps of the 
genes (representative pictures for MCF10CA1a in the left panel). 
We selected two genes with potential oncogenic role, MAML2 
and GLI2, and two tumor suppressor genes, SEMA3A and HOXA9. 
An overview of DNA methylation level at CpG sites covered on 
Illumina 450K array for MAML2 shows hypomethylation in the 
promoter and hypermethylation within the gene body in cancer 
cells (MCF10CA1a) versus ‘normal’ breast cell model (MCF10A) 
(Supplementary Figure S2A, available at Carcinogenesis Online). 
Non-regulatory region in the body is hypermethylated (red 
stars), whereas hypomethylated fragments in the body corre-
spond to enhancer regions (gray shaded areas with green stars). 
Methylation patterns of those enhancers reflect the patterns in 
the promoter that would indicate their regulatory influences. 
The profile of DNA methylation throughout MAML2 promoter 
and gene body in cancer cells is characteristic of active genes. 
Similar patterns are observed in GLI2 (Supplementary Figure 
S2B, available at Carcinogenesis Online). CpG island located in 
the gene body is heavily hypomethylated in cancer cells versus 
normal (MCF10A), which reflects patterns in the promoter and 
would be consistent with active gene transcription. Upon treat-
ment of breast cancer cells with RSV, methylation levels of CpG 
sites within enhancers of MAML2 and GLI2 rise toward the lev-
els present in normal cells (Supplementary Figure S2A and B, 
available at Carcinogenesis Online). Contrary to active oncogenes, 
tumor suppressor gene SEMA3A has hypomethylated gene body 
with no assigned regulatory role, whereas 5ʹ-UTR and enhancer 
located in the gene body are hypermethylated in cancer versus 
normal similarly to the promoter (Supplementary Figure S2C, 
available at Carcinogenesis Online). Another interesting example 
is tumor suppressor gene HOXA9, where CpG island that encom-
passes the promoter and gene body is heavily hypermethylated 
(Supplementary Figure S2D, available at Carcinogenesis Online). 
These patterns for SEMA3A and HOXA9 tumor suppressor genes 
would reflect transcriptional silencing in cancer versus normal. 
RSV exposure leads to decrease in methylation of CpG sites in 
SEMA3A enhancer and in the CpG island of GLI2, bringing the 
levels closer to the levels in normal cells.
The majority of differentially methylated CpG sites (76–82%) 
showed elevated levels of methylation after RSV treatment 
(Figure 2A–E). Interestingly, in approximately 70%, hypermeth-
ylated CpG sites were located in gene enhancers and/or CpG 
islands/shores/shelves, regions important for gene transcrip-
tion. Validation by pyrosequencing of eight hypermethylated 
CpG sites linked to eight genes, selected based on large differ-
ence and statistical significance, confirmed the distinct DNA 
methylation pattern in RSV-treated cancer cells versus con-
trol cells (Supplementary Figure S3, available at Carcinogenesis 
Online). One of the highest differences was detected for MOBP in 
MCF10CA1a cells (25% increase) and PRKG1 in MCF10CA1h (20% 
increase; Supplementary Figure S3, available at Carcinogenesis 
Online). Interestingly, both genes are involved in regulation of 
cellular signal transduction (35,36).
Hypermethylated CpG sites corresponded to 1607 genes in 
MCF10CA1h and to 2546 genes in MCF10CA1a cells (Figure 2E, list 
of genes in Supplementary Table S2, available at Carcinogenesis 
Online). Among these genes, we determined 565 genes that 
are hypermethylated in response to RSV in both breast can-
cer cell lines (Figure  2E, Supplementary Table S2, available at 
Carcinogenesis Online). This overlap was significant as measured 
by Fisher’s exact test (P = 2.2E-16). For convenience, we call this 
set of genes ‘hypermethylated RSV targets’. This group poten-
tially includes genes hypomethylated in cancer compared with 
normal tissue and RSV would act to increase their methylation 
to levels present in mammary epithelial cells. Interestingly, we 
found that 85% of hypermethylated RSV targets, whose basal 
methylation level in mammary epithelial MCF10A cells is higher 
than 0.5, are hypomethylated in breast cancer cells (Figure 2F). 
The extent of hypomethylation is more robust in highly inva-
sive MCF10CA1a cancer cells compared with lowly invasive 
MCF10CA1h cells (Figure  2F–G). Among the most hypomethyl-
ated genes in cancer, we identified several with known onco-
genic functions, including MAGEA5 (37), FCRL3 (38) and SLC2A3 
(39) (Figure  2F). Exposure to RSV increases DNA methylation 
within hypomethylated genes to a similar extent in cancer cells 
with high or low invasive properties (Figure 2G). For part of those 
genes, methylation levels come back to the levels observed 
in mammary epithelial MCF10A cells (normal cell model; 
Figure  2G). As we previously demonstrated, genes hypometh-
ylated in cancer are those with oncogenic and pro-metastatic 
functions and hypomethylation is one of the mechanisms of 
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their upregulation (10,33,40). Indeed, the bioinformatics analy-
sis using GO, KEGG and DAVID knowledgebase indicate that 
hypermethylated RSV targets are associated with functions that 
are essential for cancer formation and progression (Figure 2H). 
Furthermore, these genes are enriched in pathways, including 
MAPK, NOTCH, WNT and VEGF, which were reported before to 
drive cellular transformation, angiogenesis and metastasis 
(Figure 2I). It may suggest that these hypermethylated RSV tar-
gets are important for cancer development and progression. We 
therefore hypothesized that RSV leads to increased methylation 
within regulatory regions of these genes and causes their tran-
scriptional silencing that may be one of the mechanisms of RSV-
mediated anticancer effects. The analysis of transcription factor 
binding sites within regions hypermethylated by RSV further 
supports our hypothesis. These regions are highly enriched for 
motifs for OCT1 transcription factor that was shown to be asso-
ciated with cancer promotion (41–43). OCT1 has putative bind-
ing sites within 80% of these hypermethylated regions (TransFac 
prediction; Figure 2J).
One of the top canonical pathways associated with genes 
hypermethylated in response to RSV is NOTCH signaling 
(Figure 2I) that was shown to have oncogenic functions in breast 
cancer (17,18). One of the most robustly hypermethylated genes 
in RSV-treated cancer cells was MAML2 that acts as a positive 
regulator of NOTCH pathway (19). The difference in DNA meth-
ylation within MAML2 in RSV treated versus control cells was 
determined as 0.37 in MCF10CA1h and 0.1 in MCF10CA1a cells 
based on the array data. These elevated levels of methylation 
were identified in a fragment corresponding to the predic-
tive enhancer within MAML2 gene body (detailed map of the 
Figure 2. RSV changes the landscape of DNA methylation in breast cancer cells and increases DNA methylation in genes that are hypomethylated in breast cancer cells. 
(A,B) Pie charts of differentially methylated CpG sites with the difference of at least 0.05 between RSV-treated and control MCF10CA1h (A) and MCF10CA1a (B) breast 
cancer cells (P ˂ 0.05, limma t-test). The landscape of DNA methylation was delineated using Illumina 450K microarray platform in breast cancer cells treated with RSV 
at 15 µM for 9 days (n = 3 per group). Diff. refers to differential methylation (delta beta, RSV minus control). (C,D) Chromosomal views of differentially methylated CpG 
sites. Each CpG site with significant difference of at least 0.05 between RSV and control cells was plotted into a bar track of a chromosomal view using IGV visualization 
tool. Each bar corresponds to a single, differentially methylated CpG site, with blue indicating hypomethylation and red indicating hypermethylation in RSV versus 
control (RSV minus Ctrl). (E) Venn diagram showing overlap between the hypermethylated genes in lowly invasive MCF10CA1h and highly invasive MCF10CA1a breast 
cancer cells in response to RSV. (F,G) Basal levels of methylation of ‘hypermethylated RSV targets’ as determined by the genome-wide microarray data in untreated 
MCF10A (normal), MCF10CA1h (cancer lowly invasive) and MCF10CA1a (cancer highly invasive) cells (F), as well as in MCF10CA1h and MCF10CA1a breast cancer cells 
exposed to 15 µM RSV for 9 days (G). The basal level of methylation of these genes in breast cancer cells is compared with the methylation levels in MCF10A cells. (H,I) 
Functional analyses using GO, KEGG and DAVID knowledgebase indicate biological functions (H) and pathways (I) associated with genes corresponding to CpG sites 
hypermethylated in response to RSV in both MCF10CA1h and MCF10CA1a. (J) Transcription factors and their binding motifs enriched for RSV hypermethylated genes 
in breast cancer. Putative transcription factor binding sites were predicted using TransFac. Percentage of RSV hypermethylated genes containing the motif is indicated.
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region in array track, Figure  3A). Methylation levels achieved 
after RSV treatment in cancer cells closely reflected patterns in 
MCF10A cells (normal cell model) as shown on the array track in 
Figure 3B (representative picture for MCF10CA1h cells, please see 
Supplementary Figure S4A, available at Carcinogenesis Online, for 
pyrosequencing results). It has been demonstrated that active 
enhancers are enriched with H3K27ac (44,45). We confirmed 
by ChIP assay that this histone mark is present at MAML2 in 
cancer cells and its occupancy is significantly reduced by RSV 
(Figure 3C). These data strongly support the role of this region 
as a gene enhancer and the role of RSV in decreasing the activ-
ity of this enhancer. The detailed map in Figure 3D shows the 
exact position of CpG sites in the region targeted by RSV. Thus, 
we elaborated in the present report on epigenetic mechanisms 
of RSV in regulating MAML2 expression in breast carcinogenesis 
and consequences of this regulation for NOTCH activity.
MAML2 is epigenetically silenced in response to RSV 
and PTS, which is associated with decreased NOTCH 
signaling activity
Hypermethylation within MAML2 enhancer was quantitatively 
validated by pyrosequencing of the region encompassing three 
CpG sites that are circled and numbered in MAML2 enhancer 
map depicted in Figure 3D. Exposure of lowly and highly inva-
sive breast cancer cells to 15  μM RSV resulted in significant 
increase in methylation at CpG#2 and CpG#3 on day 9 (Figure 3E 
and F). PTS at 7 μM caused increase in methylation at CpG#2 
and/or CpG#1 in both cancer cells (Figure 3G and H). To deter-
mine whether these changes in DNA methylation are biologi-
cally relevant, we tested MAML2 expression upon treatment 
with the compounds. Using QPCR, we detected downregulation 
of MAML2 in both cancer cell lines treated with RSV or PTS for 
4 or 9 days (Figure 3I and J). The effects in invasive MCF10CA1a 
cells were stronger, especially upon RSV treatment.
If changes in methylation and expression of MAML2 in 
response to RSV or PTS are functionally relevant, attenuation 
of NOTCH signaling should be observed. Indeed, we found that 
all three NOTCH target genes that we tested are downregu-
lated upon treatment of breast cancer cells with stilbenoids 
(Figure 4). RSV and PTS caused 20–65% decrease in expression 
of the tested genes in MCF10CA1h cells at both time points, 4 
and 9 days (Figure 4A). Similar effects were observed in highly 
invasive MCF10CA1a cells (Figure 4B). As shown in Figure 4C and 
4D (representative results for RSV), the levels of expression of 
NOTCH target genes achieved upon treatments closely reflect 
the levels observed in mammary epithelial MCF10A cells (nor-
mal cell model). Expression comes back to the levels close to 
normal for all the genes and reaches normal levels for NOTCH1 
in lowly invasive MCF10CA1h cells and for HEY1 and NOTCH1 in 
highly invasive MCF10CA1a cells (Figure 4C and D).
Interestingly, in MCF10A-ras breast cancer cells that are char-
acterized by low invasive properties (Supplementary Figure S4B, 
available at Carcinogenesis Online) and low ability to anchorage-
independent growth (Supplementary Figure S4C, available at 
Carcinogenesis Online), MAML2 is expressed at a similar level 
as in mammary epithelial MCF10A cells (normal cell model) 
(Supplementary Figure S4D, available at Carcinogenesis Online). 
This corresponds to similar high DNA methylation levels of 
MAML2 enhancer in MCF10A-ras and MCF10A, as compared 
with highly invasive MCF10CA1a cells (Supplementary Figure 
S4E, available at Carcinogenesis Online), where higher MAML2 
expression is observed (Supplementary Figure S4D, available at 
Carcinogenesis Online). Furthermore, all three NOTCH target genes 
are expressed at normal levels in MCF10A-ras breast cancer cells 
(Supplementary Figure S4F, available at Carcinogenesis Online), 
which indicate low activity of NOTCH signaling. Thus, we sug-
gest that low MAML2 expression in cancer cells is associated 
with reduced NOTCH activity and low invasive potential of can-
cer cells.
Depletion of MAML2 with siRNA mimics inhibitory 
effects of stilbenoids on NOTCH signaling
If NOTCH inhibition upon treatment with stilbenoids is asso-
ciated with stilbenoid-mediated MAML2 silencing, we should 
observe similar effects on NOTCH pathway upon MAML2 deple-
tion. Indeed, MAML2 depletion in invasive MCF10CA1a cells, as 
confirmed by QPCR and western blot (Figure  5A), resulted in 
inhibition of cancer cell growth (Figure 5B) and suppression of 
NOTCH target genes (Figure 5C) as compared with cells treated 
with scrambled siRNA (siCtrl). MAML2 depletion did not affect 
the expression of WBSCR22 (MERM1), which is a non-NOTCH 
target gene involved in invasion and metastasis (46) (Figure 5D). 
Lack of the effect on WBSCR22 strengthens evidence that the 
observed decrease in cancer cell growth upon siMAML2 is a result 
of NOTCH signaling inhibition. Importantly, each of the four sets 
of siRNA present in SmartPool mixture downregulated MAML2 
expression and inhibited cancer cell growth when used sepa-
rately (Supplementary Figure S5A–C, available at Carcinogenesis 
Online). Stronger downregulation of MAML2 upon siRNA2 or 
siRNA3 corresponded to stronger inhibition of cell growth 
(Supplementary Figure S5A and B, available at Carcinogenesis 
Online). These data demonstrate that the results we present 
are not an idiosyncrasy of the siRNA sequence used and pro-
vide high confidence that we are measuring effects of MAML2 
depletion. We further show that treatment of MCF10CA1a cells 
with NOTCH signaling inhibitor, DAPT, causes similar down-
regulation of NOTCH target genes as siMAML2 (Figure 5E) and 
reduces cancer cell growth (Figure 5F). DAPT inhibits γ-secretase 
and therefore blocks cleavage of NOTCH receptor and produc-
tion of the Notch intracellular domain that translocates into 
the nucleus and transactivates the target gene. Similar effects 
observed upon siMAML2 and DAPT treatments provide strong 
support for the oncogenic role of NOTCH signaling in breast can-
cer and for MAML2 in promoting the activity of NOTCH pathway.
Chromatin condensation and transcription factor 
occupancy at MAML2 enhancer upon treatment 
with RSV
Stilbenoids, especially RSV, lead to more profound downregu-
lation of MAML2 in highly invasive cancer cells than in lowly 
invasive cells, despite similar increase in DNA methylation at 
MAML2 enhancer (Figure 3). We reasoned that other epigenetic 
marks including histone modifications may be involved in stil-
benoid-mediated regulation of MAML2 transcription. Using ChIP, 
we assessed the occupancy of H3K9acetylation (activating his-
tone mark) and H3K27tri-methylation (repressive histone mark) 
at MAML2. We found 30% decrease in H3K9ac (Figure  6A) and 
2-fold increase in H3K27me3 occupancy (Figure 6B) at the same 
region within MAML2 enhancer where higher DNA methylation 
levels were detected in response to RSV. These data indicate epi-
genetic reprogramming at the tested MAML2 region that results 
in marks characteristic of condensed chromatin structure and is 
consistent with MAML2 transcriptional silencing.
Gene silencing could be a consequence of blocked access of 
transcription factors to the recognized DNA sequence because 
of changes in the chromatin state. We computed putative tran-
scription factor binding elements within MAML2 enhancer using 
TransFac. Three transcription factors, OCT1, CEBPA and GATA1, 
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Figure  3. Hypermethylation and silencing of MAML2 in response to RSV or PTS in breast cancer cells. (A) Magnified display from chromosome 11 demonstrates 
hypermethylation within MAML2 enhancer as determined by Illumina 450K microarray (representative picture for MCF10CA1h cells, red indicating hypermethylation 
upon treatment with 15 µM RSV on day 9). The region within MAML2 enhancer containing the most significantly methylated probes is shaded in light blue. CpG site 
with the highest difference in methylation is marked with green star. (B) Illumina 450K microarray tracks demonstrating methylation levels at the most differentially 
methylated CpG site (green star) within MAML2 enhancer in mammary epithelial MCF10A cells (‘normal’ cell model) and in MCF10CA1h breast cancer cells untreated 
or treated with 15 µM RSV for 9 days. (C) Occupancy of histone H3 acetylation at lysine 27 (H3K27ac) within the MAML2 tested region in MCF10CA1a cells after 9-day 
treatment with 15 µM RSV as assessed by qChIP and expressed as a percentage of the binding level in control cells. H3K27ac marks active enhancers. (D) A map of the 
MAML2 enhancer where the light blue-shaded region represents the entire fragment tested by pyrosequencing and qChIP. The CpG sites, whose elevated methylation 
was validated by pyrosequencing, are circled and numbered. Putative transcription factor binding sites are indicated as predicted using TransFac. (E–H) Average meth-
ylation status of CpG sites in the MAML2 enhancer as determined by pyrosequencing in MCF10CA1h (E,G) and MCF10CA1a (F,H) breast cancer cells exposed for 9 days 
to 15 µM RSV (E,F) or 7 µM PTS (G,H). Numbers in X axis correspond to CpG sites within the tested region. (I,J) The effects of 4 day- and 9 day-treatment with 15µM RSV or 
7 µM PTS on expression of MAML2 in MCF10CA1h (I) or MCF10CA1a (J) breast cancer cells as determined by QPCR. All results represent mean ± SD of three independent 
experiments; ***P < 0.001, **P < 0.01, *P < 0.05.
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were found to have predictive binding sites at the region encom-
passing three CpG sites assessed in pyrosequencing (Figure 3D). 
As shown in Figure 2J, motifs for OCT1 were found to be the most 
common within regions hypermethylated by RSV. We therefore 
explored OCT1 binding to MAML2 and tested how this binding 
is affected by stilbenoid-mediated epigenetic changes within 
MAML2 enhancer. Using ChIP, we confirmed OCT1 binding to 
MAML2 enhancer (Figure 6C, control cells). The binding dramati-
cally decreases upon treatment of MCF10CA1a with 15 μM RSV 
(Figure  6C). The lack of OCT1 binding may be directly linked 
to MAML2 transcriptional silencing. To test this hypothesis, 
we depleted OCT1 in MCF10CA1a cells using SmartPool siRNA 
mixture and four siRNA sequences separately, as confirmed by 
QPCR and western blot (Figure 6D, Supplementary Figure S5D–F, 
available at Carcinogenesis Online) and tested the effect of OCT1 
absence on MAML2 expression (Figure 6D and E). Indeed, OCT1 
depletion led to substantial MAML2 downregulation (Figure 6E) 
and produced similar effects on cancer cell growth as siMAML2 
(Supplementary Figure S5D, available at Carcinogenesis Online). 
These findings suggest the role of OCT1 in regulation of MAML2 
transcription.
DNMT3B occupancy at MAML2 enhancer is 
increased upon treatment with RSV
Stilbenoids lead to increase in DNA methylation within MAML2 
enhancer that coincides with MAML2 transcriptional silencing. 
DNA methylation reaction is catalyzed by DNA methyltrans-
ferases, including maintenance DNMT1, and de novo DNMT3A 
Figure 4. Epigenetic silencing of MAML2 in response to RSV or PTS is associated with attenuation of the activity of the NOTCH signaling pathway. (A,B) The effects of 
4-day and 9-day treatment with 15 µM RSV or 7 µM PTS on expression of NOTCH target genes, HES1, HEY1 and NOTCH1, in MCF10CA1h (A) and MCF10CA1a (B) breast 
cancer cells as determined by QPCR. Expression was expressed as a percentage of mRNA levels in untreated cells (% control). (C,D) Levels of expression of NOTCH target 
genes in untreated mammary epithelial MCF10A cells (‘normal’ cell model) and in MCF10CA1h (C) and MCF10CA1a (D) breast cancer cells untreated or upon 9-day 
treatment with 15 µM RSV. Expression was assessed by QPCR and expressed as a percentage of mRNA levels in untreated cancer cells (% control). All results represent 
mean ± SD of three independent experiments; ***P < 0.001, **P < 0.01, *P < 0.05.
K.Lubecka et al. | 665
and 3B. While RSV and PTS caused attenuation or no change of 
DNMT1 and DNMT3A, we detected upregulation of DNMT3B in 
breast cancer cells (Figure 6F, Supplementary Figure S6, available 
at Carcinogenesis Online). A question arose whether DNMT3B is 
involved in stilbenoid-mediated increased methylation within 
MAML2. We therefore tested DNMT3B binding using ChIP. 
Treatment with 15 μM RSV led to DNMT3B enrichment at MAML2 
enhancer in MCF10CA1a cells, whereas no binding was detected 
in control untreated cells (Figure  6G). The fragment bound by 
DNMT3B overlapped with the fragment whose increased meth-
ylation was detected by microarray and pyrosequencing. It sug-
gests the role of DNMT3B in increased methylation of MAML2 
upon RSV exposure.
Discussion
Attention in the field of epigenetic cancer research has been 
focused on the increase in DNA methylation of tumor suppres-
sor genes as an early event in cancer development (47). It is well 
accepted that promoter hypermethylation leads to silencing of 
tumor suppressor genes and that reversal of repression of these 
genes results in anticancer effects (5,6). Hence, the main focus 
in epigenetic pharmacology was on developing strategies that 
will inhibit DNA methylation and remove aberrant methylation 
marks from tumor suppressor genes. However, it is becoming 
clear that promoter hypomethylation is as prevalent in cancer as 
hypermethylation (10). Recent genome-wide DNA methylation 
studies in cancer report a similar number of hypomethylated 
and hypermethylated gene promoters (10,13,48). Interestingly, 
the hypomethylated genes share common functions relevant to 
cancer promotion. Our recent studies show that differentially 
methylated genes that distinguish noninvasive cancer cells 
from highly invasive cells include predominantly genes that 
are hypomethylated in invasive cells and may account for their 
highly invasive potential (24,49). These pieces of evidence indi-
cate a need for developing therapeutic strategies that would be 
aimed at reversal of both hypermethylation of tumor suppres-
sor genes and hypomethylation of genes with cancer-promot-
ing functions (e.g. oncogenes and pro-metastatic genes). Such 
compounds would mediate subtle changes in the DNA methyla-
tion patterns rather than dramatic off–on changes and lead to 
reprogramming of multiple functional gene networks. Excellent 
candidates for such action are naturally derived compounds, 
such as RSV and PTS, which bring about profound phenotypic 
changes at minimally toxic doses. Indeed, the global picture 
emerging from our genome-wide DNA methylation study is that 
most of the changes in DNA methylation in response to RSV are 
moderate indicating reprogramming of the patterns (Figure 2).
We and others previously observed that RSV modulates 
DNA methylation within promoters of tumor suppressor genes 
leading to reactivation of those genes in breast cancer (5,6,21). 
However, the effects on oncogenes and pro-metastatic genes are 
still largely unknown. One would expect that anticancer action 
of RSV will be associated with downregulation of oncogenes and 
pro-metastatic genes, contrary to the effects on tumor suppres-
sor genes observed so far. In the present study, we tested the 
possibility that stilbenoids remodel the DNA methylation land-
scape in breast cancer and target genes with oncogenic function 
Figure 5. Functional role of MAML2 in regulation of the NOTCH signaling pathway. (A) MAML2 expression quantified by QPCR after first (I), second (II) and third (III) 
transfection and by western blot after second transfection with scrambled siRNA (siCtrl) or siRNA directed to MAML2 (siMAML2). (B) Effect on cell growth after first (day 
3), second (day 6) and third (day 9) transfection with siCtrl or siMAML2. (C,D) Effect of MAML2 depletion (second transfection) on expression of NOTCH target genes, 
HES1, HEY1 and NOTCH1 (C), and on a non-NOTCH target gene, WBSCR22 (D), in MCF10CA1a breast cancer cells as determined by QPCR. (E) Effect of 72-h exposure 
to NOTCH inhibitor, DAPT, at 100 µM concentration, on expression of NOTCH target genes, HES1, HEY1 and NOTCH1, as determined by QPCR and on cell growth in 
MCF10CA1a breast cancer cells. All results represent mean ± SD of three independent experiments; ***P < 0.001, **P < 0.01, *P < 0.05.
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for methylation and silencing. This would account, at least par-
tially, for the anticancer action of these compounds. Treatment 
with stilbenoids resulted in a dose- and time-dependent inhibi-
tion in cell proliferative and invasive properties in breast cancer 
cells (Figure 1). These effects were cancer specific, as only mar-
ginal changes in cell viability were detected in mammary epi-
thelial MCF10A cells within a dose range of 0–20 µM (Figure 1). 
One possible explanation for this remarkable observation is that 
RSV and PTS affect genes that are dysregulated in cancer but not 
in normal cells. For instance, the compounds lead to silencing of 
genes that are activated in cancer. Since these genes are already 
silenced in normal cells, the compounds would have no impact 
on these genes.
We propose a model whereby stilbenoids reduces tumo-
rigenic features and metastatic potential of cancer cells by 
increased DNA methylation and silencing of genes and signal-
ing pathways that promote cancer. Genome-wide analysis of 
the DNA methylation landscape in breast cancer cells revealed 
remodeling of the patterns in response to RSV (Figure 2). Indeed, 
the majority of differentially methylated CpG sites were hyper-
methylated in response to RSV versus control (Figure  2A–D, 
Supplementary Figure S3, available at Carcinogenesis Online). 
These hypermethylated CpG sites were predominantly located 
in genes involved in critical oncogenic signaling pathways and 
functions essential for cancer development and progression 
(Figure  2H and I). The increase in DNA methylation could be 
potentially linked to silencing of these genes and mediate anti-
cancer effects of stilbenoids. This is further supported by our 
next observation. When we compared the basal methylation 
levels of hypermethylated RSV targets between cancer cells and 
MCF10A cells (our normal cell model), we found that most of the 
genes targeted by RSV are highly methylated in normal cells and 
lose methyl marks in cancer cells (Figure 2F). Thus, their meth-
ylation levels are coming back toward normal levels upon RSV 
treatment (Figure 2G). Genes that are the most demethylated in 
cancer cells and targeted by RSV for increase in methylation are 
listed in the right panel of Figure 2F. Functional analysis of these 
genes indicates that they are involved in tumor progression 
(MAGEA5, FCRL3) (37,38), angiogenesis (MEGF6) (50), increase in 
migration of metastatic cancer cells (PTPRN2, SCGN) (51,52) and 
stimulation of cell proliferation (SCGN, SLC2A3) (39).
One of the pathways associated with genes hypermethyl-
ated in response to RSV (Figure  2E) is NOTCH signaling with 
reported oncogenic role in breast cancer (17,18). Thus, targeting 
Figure 6. Changes in histone modifications and in occupancy of DNMT3B and transcription factor OCT1 within MAML2 enhancer in breast cancer cells in response 
to RSV; functional role of OCT1 in regulation of MAML2 expression. (A–C) Occupancy of histone H3 acetylation at lysine 9 (H3K9ac, activating mark) (A), histone H3 
trimethylation at lysine 27 (H3K27me3, repressive mark) (B) and transcription factor OCT1 (C) within the MAML2 enhancer in MCF10CA1a cells in response to 9-day 
treatment with 15 µM RSV as assessed by qChIP and expressed as a percentage of the binding level in control cells. (D) OCT1 expression quantified by QPCR and western 
blot after first transfection with scrambled siRNA (siCtrl) or siRNA directed to OCT1 (siOCT1). (E) Effect of OCT1 depletion (first transfection) on expression of MAML2 
in MCF10CA1a breast cancer cells as determined by QPCR. (F) Effect of 9-day treatment with 15 µM RSV on DNMT3B expression in MCF10CA1a breast cancer cells as 
determined by QPCR. (G) Binding of DNMT3B to the MAML2 tested region in MCF10CA1a cells in response to 9-day treatment with 15 µM RSV as assessed by qChIP. (H) 
The scheme displaying changes in DNA methylation, histone marks and occupancy of DNMT3B and OCT1 at MAML2 enhancer in response to RSV, as suggested by our 
study. All results represent mean ± SD of three independent experiments; ***P < 0.001, **P < 0.01, *P < 0.05.
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this pathway may be an important therapeutic strategy in breast 
cancer. Our genome-wide study in RSV-treated breast cancer 
cells indicated increase in methylation within the enhancer 
region of MAML2 (Figure 3) that is a coactivator of NOTCH tar-
get genes (19,20). Higher DNA methylation levels at MAML2 
enhancer were linked to decrease in occupancy of H3K27ac 
(Figure  3C) that is a histone modification specific to active 
enhancers (45,46). Furthermore, we detected decrease in acti-
vating and increase in repressive histone marks at this region 
(Figure 6A and B). Cumulatively, these changes in DNA methyla-
tion and histone modifications at MAML2 enhancer in response 
to stilbenoids suggest condensed chromatin structure and could 
account for observed decrease in MAML2 expression (Figure 3I 
and J). Interestingly, both RSV and PTS were demonstrated to 
exert similar mode of action on the expression of several genes 
in rat diabetic models where DNA methylation and silencing 
were detected in response to the compounds (22,23).
Epigenetic silencing of MAML2 in response to RSV should 
have consequences for the activity of NOTCH signaling (19,20). 
We found that stilbenoids downregulate all three targets of the 
pathway suggesting negative regulation of signal transduction 
(Figure 4). MAML2 knockdown exerts similar effects (Figure 5). It 
indicates the functional link between MAML2 and NOTCH and 
suggests that the effects of stilbenoids on NOTCH signaling are at 
least partially linked to stilbenoid-mediated MAML2 epigenetic 
silencing. Our results are consistent with a recent report where 
NOTCH pathway was shown to be attenuated by RSV in cervical 
cancer (53). With the present findings, we deliver insights into 
the mechanisms of regulation of the pathway by stilbenoids and 
their relevance in breast carcinogenesis. Epigenetic targeting of 
MAML2 and subsequently NOTCH pathway may have impor-
tant in vivo implications. Publicly available genome-wide data 
show hypomethylation of MAML2 enhancer in breast tumors 
compared with normal breast tissue (TCGA, Supplementary 
Figure S7A, available at Carcinogenesis Online) and overexpres-
sion of MAML2 in breast tumors and other cancers (Oncomine, 
Supplementary Figure S7B, available at Carcinogenesis Online). In 
addition, we observe robust upregulation of Maml2 and Notch 
target genes in cancer versus normal in N-methyl nitrosourea-
induced mammary carcinogenesis in Sprague–Dawley rats 
(Supplementary Figure S7C, available at Carcinogenesis Online). 
These pieces of evidence give strong support for future investi-
gations of in vivo effects of stilbenoids on epigenetic regulation 
of oncogenic NOTCH pathway and tumor formation.
What mechanism is responsible for stilbenoid-mediated 
increase in DNA methylation at MAML2 enhancer? The clas-
sic explanation would involve DNA methyltransferases. We 
found that de novo methyltransferase DNMT3B binds to MAML2 
enhancer upon treatment with stilbenoids (Figure 6G). This coin-
cides with decrease in OCT1 occupancy (Figure  6C). Our find-
ings indicate that OCT1 is a candidate transcription factor that 
regulates MAML2 transcription. It binds to MAML2 enhancer in 
untreated cancer cells (Figure 6C) and its depletion with siRNA 
leads to MAML2 suppression and mimics the effects of siMAML2 
on cancer cell growth (Figure 6D and E, Supplementary Figure 
S5D, available at Carcinogenesis Online). Importantly, regions 
hypermethylated in response to RSV based on the array data are 
highly enriched for OCT1 motifs (TransFac). These RSV-targeted 
regions are located in genes that are associated with oncogenic 
signaling and other cancer-promoting functions (Figure  2H–I), 
including genes that are strongly demethylated in cancer cells 
compared with mammary epithelial MCF10A cells (normal cell 
model) (Figure 2F and G). Their oncogenic potential is consist-
ent with OCT1 function as an enhancer of tumor malignancy 
(41–43). It raises an interesting question whether OCT1 dictates 
specificity of stilbenoids in targeting this set of genes for hyper-
methylation. This intriguing hypothesis remains to be tested in 
future projects.
Our findings support a model of stilbenoids action proposed 
in Figure 6H. In breast cancer cells, MAML2 is expressed that is 
associated with low DNA methylation at MAML2 enhancer and 
enrichment with H3K27ac and H3K9ac (open chromatin struc-
ture). Hence, OCT1 binds to its recognized sequence within this 
region, the gene is transcribed and NOTCH signaling is active. In 
the presence of RSV, chromatin structure becomes condensed 
gaining DNA methylation and H3K27me3. OCT1 binding is 
impaired and DNMT3B binding is facilitated that may under-
lie DNA methylation and transcriptional silencing (Figure  6H). 
Interestingly, RSV brings methylation levels within MAML2 
very close to the levels observed in normal cells (Figure  3B, 
Supplementary Figure S4A, available at Carcinogenesis Online). 
Changes in methylation coexist with changes in histone modi-
fications as presented in Figures 3 and 6. This suggests DNA 
methylation and histone modifications can cooperate together 
to affect gene expression and thus the anticancer effect of 
RSV. This might be a general pattern for genes targeted by RSV 
because methylation levels for some RSV targets increase but do 
not reach normal levels (Figure 2G).
In the present study, we determine for the first time genome-
wide landscapes of DNA methylation in response to RSV. Our 
findings reveal that stilbenoids target for methylation genes 
with oncogenic and pro-metastatic function, many of which 
are regulators of signaling pathways critical in cancer such as 
NOTCH among others. Stilbenoids lead to epigenetic silencing 
of MAML2, the activator of NOTCH pathway, which is associated 
with increased occupancy of DNMT3B and decreased binding of 
OCT1 transcription factor at MAML2 enhancer. Suppression of 
MAML2 results in inactivation of NOTCH signaling. We deliver 
here scientific evidence for stilbenoids as agents that could 
combat epigenetic activation of genes involved in breast cancer 
development and progression and hence could be effective in 
anticancer strategies.
Supplementary material
Supplementary Materials, Supplementary Figures S1–S7 and 
Supplementary Tables S1 and S2 can be found at http://carcin.
oxfordjournals.org/
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